These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 27648712)

  • 1. The Prognostic Value of Plasma YKL-40 in Patients With Chemotherapy-Resistant Ovarian Cancer Treated With Bevacizumab.
    Boisen MK; Madsen CV; Dehlendorff C; Jakobsen A; Johansen JS; Steffensen KD
    Int J Gynecol Cancer; 2016 Oct; 26(8):1390-8. PubMed ID: 27648712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer.
    Secord AA; McCollum M; Davidson BA; Broadwater G; Squatrito R; Havrilesky LJ; Gabel AC; Starr MD; Brady JC; Nixon AB; Duska LR
    Gynecol Oncol; 2019 Jun; 153(3):555-561. PubMed ID: 30929823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated preoperative plasma D-dimer level is a useful predictor of chemoresistance and poor disease outcome for serous ovarian cancer patients.
    Liu P; Wang Y; Tong L; Xu Y; Zhang W; Guo Z; Ni H
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1163-71. PubMed ID: 26542279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer.
    Dehn H; Høgdall EV; Johansen JS; Jørgensen M; Price PA; Engelholm SA; Høgdall CK
    Acta Obstet Gynecol Scand; 2003 Mar; 82(3):287-93. PubMed ID: 12694127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic importance of cell-free DNA in chemotherapy resistant ovarian cancer treated with bevacizumab.
    Steffensen KD; Madsen CV; Andersen RF; Waldstrøm M; Adimi P; Jakobsen A
    Eur J Cancer; 2014 Oct; 50(15):2611-8. PubMed ID: 25087181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer.
    Slaughter KN; Thai T; Penaroza S; Benbrook DM; Thavathiru E; Ding K; Nelson T; McMeekin DS; Moore KN
    Gynecol Oncol; 2014 Apr; 133(1):11-5. PubMed ID: 24680585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy.
    Previs RA; Bevis KS; Huh W; Tillmanns T; Perry L; Moore K; Chapman J; McClung C; Kiet T; Java J; Chan J; Secord AA
    Gynecol Oncol; 2014 Mar; 132(3):531-6. PubMed ID: 24472410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial.
    Boisen MK; Holst CB; Consalvo N; Chinot OL; Johansen JS
    Oncotarget; 2018 Jan; 9(6):6752-6762. PubMed ID: 29467925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study.
    Ferriss JS; Java JJ; Bookman MA; Fleming GF; Monk BJ; Walker JL; Homesley HD; Fowler J; Greer BE; Boente MP; Burger RA
    Gynecol Oncol; 2015 Oct; 139(1):17-22. PubMed ID: 26216729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Independent radiologic review of AURELIA, a phase 3 trial of bevacizumab plus chemotherapy for platinum-resistant recurrent ovarian cancer.
    Husain A; Wang Y; Hanker LC; Ojeda B; Anttila M; Breda E; Vuylsteke P; Pujade-Lauraine E
    Gynecol Oncol; 2016 Sep; 142(3):465-70. PubMed ID: 27184721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival.
    Høgdall EV; Johansen JS; Kjaer SK; Price PA; Christensen L; Blaakaer J; Bock JE; Glud E; Høgdall CK
    Oncol Rep; 2003; 10(5):1535-8. PubMed ID: 12883737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple genetic variants predict the progression-free survival of bevacizumab plus chemotherapy in advanced ovarian cancer: A retrospective study.
    Gao J; Li F; Liu Z; Huang M; Chen H; Liao G; Meng J; Wang Q; Zhao H; Li C; Ji J; Cai S; Du N
    Medicine (Baltimore); 2021 Sep; 100(35):e27130. PubMed ID: 34477158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
    Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
    Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Identification and prognostic value of differentially expressed proteins of patients with platinum resistance epithelial ovarian cancer in serum].
    Wu WJ; Wang Q; Zhang W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2016 Jul; 51(7):515-23. PubMed ID: 27465871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer.
    Vallius T; Hynninen J; Auranen A; Matomäki J; Oksa S; Roering P; Grènman S
    Tumour Biol; 2017 Feb; 39(2):1010428317691189. PubMed ID: 28218038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic and predictive value of YKL-40 in stage IIB-III melanoma.
    Krogh M; Christensen I; Bouwhuis M; Johansen JS; Nørgaard P; Schmidt H; Hansson J; Suciu S; Eggermont AM; Bastholt L;
    Melanoma Res; 2016 Aug; 26(4):367-76. PubMed ID: 27076041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses.
    Bais C; Mueller B; Brady MF; Mannel RS; Burger RA; Wei W; Marien KM; Kockx MM; Husain A; Birrer MJ;
    J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of human epididymis protein 4 in epithelial ovarian cancer.
    Paek J; Lee SH; Yim GW; Lee M; Kim YJ; Nam EJ; Kim SW; Kim YT
    Eur J Obstet Gynecol Reprod Biol; 2011 Oct; 158(2):338-42. PubMed ID: 21683503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer.
    Diefenbach CS; Shah Z; Iasonos A; Barakat RR; Levine DA; Aghajanian C; Sabbatini P; Hensley ML; Konner J; Tew W; Spriggs D; Fleisher M; Thaler H; Dupont J
    Gynecol Oncol; 2007 Feb; 104(2):435-42. PubMed ID: 17023034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum Vascular Endothelial Growth Factor-A as a Prognostic Biomarker for Epithelial Ovarian Cancer.
    Komatsu H; Oishi T; Itamochi H; Shimada M; Sato S; Chikumi J; Sato S; Nonaka M; Sawada M; Wakahara M; Umekita Y; Harada T
    Int J Gynecol Cancer; 2017 Sep; 27(7):1325-1332. PubMed ID: 28557832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.